Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 By Ogkologos - July 1, 2025 605 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KOMET study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with... April 26, 2022 Joining the dots: How our new research data strategy will unlock... July 7, 2022 Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis April 10, 2025 This Bar of Soap with a Lump Will Help You Remember... May 31, 2019 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Sugemalimab Blood Test Accurately Detects Early-Stage Pancreatic Cancer Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in... COVID-19 vaccine and cancer – latest updates
